# PRX-115 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/prx-115

> The next catalyst for PRX-115, sponsored by Protalix BioTherapeutics, Inc. (PLX), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | PRX-115 |
| Codes | PRX-115 |
| Sponsor | Protalix BioTherapeutics, Inc. (PLX) https://sec-api.dev/companies/plx/catalysts |
| Indications | [uncontrolled gout](https://sec-api.dev/indications/uncontrolled-gout), gout during the second half of 2025, [Gout](https://sec-api.dev/indications/gout) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC Form 10-K (accession 0001558370-25-003039): "In March 2023, we initiated a phase I First-in-Human clinical trial of PRX-115." https://www.sec.gov/Archives/edgar/data/1006281/000155837025003039/plx-20241231x10k.htm

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001558370-24-015612): "In March 2024, the Company initiated a phase I First-in-Human clinical trial of PRX-115." https://www.sec.gov/Archives/edgar/data/1006281/000155837024015612/plx-20240930x10q.htm

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2. Indication: gout during the second half of 2025.
- First seen 2025-03-17, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003036): ""We are pleased with the promising results from our first-in-human study of our gout candidate, PRX-115, in adult volunteers with elevated uric acid levels, and hope to build on this momentum with the goal of initiating a phase II clinical trial in patients with gout during the second half of 2025." https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-003039): "We have completed a phase I First-in-Human clinical trial of PRX-115 and we expect to commence a phase II clinical trial of PRX-115 in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1006281/000155837025003039/plx-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011468): "We anticipate initiation of a randomized Phase 2 trial in the second half of 2025 and enrollment of the first patient in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/plx-20250814xex99d1.htm

### Sep 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-10-17, last confirmed 2026-02-11.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-013498): "FDA accepted BLA for review Sept 2025)" https://www.sec.gov/Archives/edgar/data/1006281/000110465926013498/plx-20260211xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-100264): "FDA accepted BLA Sept 2025)" https://www.sec.gov/Archives/edgar/data/1006281/000110465925100264/plx-20251017xex99d1.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Gout.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07280156 (A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Protalix." https://clinicaltrials.gov/study/NCT07280156

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Gout.
- First seen 2026-03-18, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07280156 (A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Protalix." https://clinicaltrials.gov/study/NCT07280156
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124761): "We look forward to top-line results from the RELEASE study in the second half of 2027."" https://www.sec.gov/Archives/edgar/data/1006281/000110465926124761/plx-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124761): "Top-line results are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1006281/000110465926124761/plx-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-094433): "The Company continues to anticipate top-line results in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059749): "The Company continues to anticipate top-line results in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-029846): "The Company anticipates top-line results in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/plx-20260318xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-064850): "Top-line results anticipated in 2H 2027" https://www.sec.gov/Archives/edgar/data/1006281/000110465926064850/plx-20260521xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124761): "The PRX-115 Phase 2 RELEASE study remains on track, aiming to improve adherence and durability of response in uncontrolled gout, a substantial unmet need; top-line results anticipated in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1006281/000110465926124761/plx-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124761): "Patient enrollment continues in the Company's Phase 2 RELEASE study (NCT07280156) of PRX-115, a recombinant PEGylated uricase, for the treatment of uncontrolled gout; anticipated top-line results in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1006281/000110465926124761/plx-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-094433): "PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059749): "PRX-115 Phase 2 study continues to advance as planned with top-line results anticipated in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513xex99d1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/prx-115.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PRX-115 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/prx-115

```bibtex
@misc{secapidev_pdufa_prx_115_20261116,
  title        = {PRX-115 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/prx-115}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_prx_115_20261116","title":"PRX-115 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/prx-115","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
